| Takeover Speculation Swarms at AspenBio Pharma It seems like AspenBio Pharma (NASDAQ:APPY) is being talked about on just about every corner down Wall Street, and not without merit [see company description below]. We first wrote a report entitled “Is AspenBio Pharma Next To Follow In The Footsteps Of Dendreon (DNDN) and Human Genome Sciences (HGSI)?” on April 21st, and since then, the share price has gained more than $1.10, going from $2.65 to $3.74, and reaching a high of $4.00, which is near the 200 DMA. The latest developments have several well known sources indicating that a partnership, or even a high profile takeover, could be in store for AspenBio. “No other such test exists. A test for appendicitis has the potential to revolutionize emergency medicine, decrease unnecessary surgeries, reduce costs and save many lives,” says Sean Lavin, a medical doctor and analyst at Oppenheimer & Co. According to Lavin, the market opportunity for AspenBio’s appendicitis test is $1.8 billion in the U.S. and $6 billion in other countries.Complete Story » seekingalpha.com |
Drug Makers Share Alzheimer's Data Drug makers' attempts to find treatments for Alzheimer's disease have produced scant results and a long string of busts. Now a broad effort is under way to learn something from those failures. online.wsj.com |
Celgene: Growth by Acquisition Jason Chew submits: During the last decade, Celgene (CELG) has been one of the best performing stocks. With a market cap in the year 2000 of just $2.4 billion, it has grown to become the third largest biotech company behind Amgen (AMGN) and Gilead (GILD), sporting a $22.9 billion market cap; however, that is down from its recent high of over $30 billion. Its stock has been trending downward since 2008.Its top drug, Revlimid, was initially approved in 2005 for a subset of myelodysplastic syndrome (MDS) patients after a highly successful Phase II trial. It went on to gain approval in multiple myeloma (MM), with sales hitting $1.7 billion in 2009. Complete Story » seekingalpha.com |
Cigarette Machines Help Evade Tax Scores of tobacco retailers are taking advantage of a federal tax loophole to offer deep discounts on roll-your-own cigarettes. But the practice is attracting scrutiny from regulators and cigarette manufacturers. online.wsj.com |
Chelsea Therapeutics Shares Fly on Hypotension Drug Trials Promise Biopharmaceutical company Chelsea Therapeutics International (Nasdaq:CHTP) soared 30% in morning trading on Monday based on the preliminary results of its phase III study of Northera, a drug used to treat the symptoms of a disease that causes a debilitating drop in blood pressure upon standing. Chelsea said that the preliminary analysis of the trial met its multiple endpoints, showing that treatment with Northera improved the symptoms of patients suffering from neurogenic orthostatic hypotension (NOH) and proved that the drug was both safe and well tolerated.Complete Story » seekingalpha.com |